At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 712 enrolled
Drug / intervention
Ranibizumab +1 moredrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)
In Brief
A Phase 4 clinical trial evaluating Ranibizumab and Aflibercept for Neovascular Age-related Macular Degeneration. Completed, enrolled 712 participants across 68 sites in 10 countries.
Detailed Summary
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Belgium, Denmark, France, Germany, Netherlands, Norway, Portugal, Sweden, Switzerland
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartOct 2013
Primary CompletionNov 2016
Study CompletionMay 2017
TodayJul 2026
First PostedOct 9, 2013
Enrollment StartOct 23, 2013
Primary CompletionNov 22, 2016
Study CompletionMay 29, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.7 years ago
Interventions
Ranibizumabdrug
0.5 mg intravitreal injection
Afliberceptdrug
2 mg intravitreal injection